Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 34 articles: HTML format

Single Articles

September 2024
1. SPICER JD, Garassino MC, Wakelee H, Liberman M, et al
   Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3
   Lancet. 2024 Sep 12:S0140-6736(24)01756-2. doi: 10.1016/S0140-6736(24)01756.
   PubMed     Abstract available
   
   
   
2. PRESLEY CJ, Owen DH
   Improved survival for patients with lung cancer treated with perioperative immunotherapy.
   Lancet. 2024 Sep 12:S0140-6736(24)01920-2. doi: 10.1016/S0140-6736(24)01920.
   PubMed    
   
   
   August 2024
3. MEYER ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, et al
   New promises and challenges in the treatment of advanced non-small-cell lung cancer.
   Lancet. 2024 Aug 6:S0140-6736(24)01029-8. doi: 10.1016/S0140-6736(24)01029.
   PubMed     Abstract available
   
   
   July 2024
4. CHANG JY, Verma V, Heymach JV
   Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer - Authors' reply.
   Lancet. 2024;404:241-242.
   PubMed    
   
   
   
5. HINDIE E
   Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
   Lancet. 2024;404:241.
   PubMed    
   
   
   
6. JIANG L, Yu J, Meng X
   Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
   Lancet. 2024;404:240-241.
   PubMed    
   
   
   June 2024
7. THE LANCET
   Lung cancer treatment: 20 years of progress.
   Lancet. 2024;403:2663.
   PubMed    
   
   
   May 2024
8. GIJTENBEEK RG, Noordhof AL, Asmara OD, Groen HJ, et al
   Immunotherapy in frail non-small-cell lung cancer patients.
   Lancet. 2024;403:1986.
   PubMed    
   
   
   March 2024
9. MUROYA D, Morimitsu Y, Nakamura K, Hayashi K, et al
   Hidden metastatic lung tumour diagnosed by AI.
   Lancet. 2024;403:1290.
   PubMed    
   
   
   
10. EDERHY S, Cadranel J, Granger C, Hammoudi N, et al
    Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
    Lancet. 2024;403:860-861.
    PubMed    
    
    
    January 2024
11. PAZ-ARES L, Mehta B, Wang Y, Obiozor C, et al
    Sotorasib in KRAS(G12C) mutated lung cancer - Authors' reply.
    Lancet. 2024;403:145-146.
    PubMed    
    
    
    
12. OLIVIER T, Prasad V
    Sotorasib in KRAS(G12C) mutated lung cancer.
    Lancet. 2024;403:145.
    PubMed    
    
    
    
13. HANNA GG, McDonald F
    SBRT for oligoprogressive disease: using the evidence to maximise the benefits.
    Lancet. 2024;403:122-124.
    PubMed    
    
    
    December 2023
14. CHU Q, Perrone F, Greillier L, Tu W, et al
    Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
    Lancet. 2023;402:2295-2306.
    PubMed     Abstract available
    
    
    
15. LEE YCG
    Pembrolizumab plus chemotherapy for pleural mesothelioma.
    Lancet. 2023;402:2266-2267.
    PubMed    
    
    
    
16. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available
    
    
    November 2023
17. SALMAN M, Fernandez Crespo R, Judah G
    Impact of messaging informed by behavioural science on uptake of targeted lung health checks: a service evaluation.
    Lancet. 2023;402 Suppl 1:S82.
    PubMed     Abstract available
    
    
    July 2023
18. BROOKS ED
    Safe and effective systemic therapy for early-stage non-small-cell lung cancer.
    Lancet. 2023 Jul 18:S0140-6736(23)01464-2. doi: 10.1016/S0140-6736(23)01464.
    PubMed    
    
    
    
19. CHANG JY, Lin SH, Dong W, Liao Z, et al
    Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Lancet. 2023 Jul 18:S0140-6736(23)01384-3. doi: 10.1016/S0140-6736(23)01384.
    PubMed     Abstract available
    
    
    
20. O'SULLIVAN H, Popat S
    Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible.
    Lancet. 2023 Jul 6:S0140-6736(23)00807-3. doi: 10.1016/S0140-6736(23)00807.
    PubMed    
    
    
    
21. LEE SM, Schulz C, Prabhash K, Kowalski D, et al
    First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled stu
    Lancet. 2023 Jul 6:S0140-6736(23)00774-2. doi: 10.1016/S0140-6736(23)00774.
    PubMed     Abstract available
    
    
    April 2023
22. SLATER S, Cunningham D
    Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer.
    Lancet. 2023 Apr 14:S0140-6736(23)00767-5. doi: 10.1016/S0140-6736(23)00767.
    PubMed    
    
    
    February 2023
23. GOLDBERG SB, Herbst RS
    The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.
    Lancet. 2023 Feb 9:S0140-6736(23)00288-X. doi: 10.1016/S0140-6736(23)00288.
    PubMed    
    
    
    
24. DE LANGEN AJ, Johnson ML, Mazieres J, Dingemans AC, et al
    Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial.
    Lancet. 2023 Feb 7:S0140-6736(23)00221-0. doi: 10.1016/S0140-6736(23)00221.
    PubMed     Abstract available
    
    
    December 2022
25. ADAMS SJ, Stone E, Baldwin DR, Vliegenthart R, et al
    Lung cancer screening.
    Lancet. 2022 Dec 20:S0140-6736(22)01694-4. doi: 10.1016/S0140-6736(22)01694.
    PubMed     Abstract available
    
    
    September 2022
26. THE LANCET
    COPD: from an end-stage disease to lifelong lung health.
    Lancet. 2022;400:863.
    PubMed    
    
    
    April 2022
27. SAJI H, Okada M, Tsuboi M, Nakajima R, et al
    Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
    Lancet. 2022;399:1607-1617.
    PubMed     Abstract available
    
    
    
28. THE LANCET
    Cancer care: beyond survival.
    Lancet. 2022;399:1441.
    PubMed    
    
    
    September 2021
29. FELIP E, Altorki N, Zhou C, Csoszi T, et al
    Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02098.
    PubMed     Abstract available
    
    
    
30. GAINOR JF
    Adjuvant PD-L1 blockade in non-small-cell lung cancer.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02100.
    PubMed    
    
    
    July 2021
31. BAAS P, Scherpereel A, Nowak AK, Oukessou A, et al
    Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
    Lancet. 2021;398:302.
    PubMed    
    
    
    
32. DI MAIO M, Tagliamento M
    Heterogeneity of treatment effects in malignant pleural mesothelioma.
    Lancet. 2021;398:301-302.
    PubMed    
    
    
    
33. THAI AA, Solomon BJ, Sequist LV, Gainor JF, et al
    Lung cancer.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00312.
    PubMed     Abstract available
    
    
    January 2021
34. TREASURE T, Macbeth F, Farewell V, Williams NR, et al
    The fallacy of large survival gains from lung metastasectomy in colorectal cancer.
    Lancet. 2021;397:97-98.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.